COVID-19
Conditions
Brief summary
This study is an observational study (Non-interventional study) to evaluate the safety and efficacy of favipiravir in patients older than 15 years of age, diagnosed with COVID-19 and initiated treatment with favipiravir before enrollment to the study. Patients who have already had a routine favipiravir treatment decision or alternatively favipiravir treatment started at the time of enrollment, will be included in this study.
Detailed description
The clinical picture of 2019-nCoV disease is in a broad spectrum, which includes asymptomatic infection, a mild upper respiratory tract infection, respiratory failure, and even severe viral pneumonia with death. Although the mortality rate is not yet clear, the reported case-fatality risk was 11-14% during the initial studies which included patients with severe disease. The overall case fatality rate was reported as approximately 2%. In addition, most cases have resulted in a pneumonia requiring supplemental oxygen therapy and ventilator support. The alarming levels of spread and severity of COVID-19 caused a global emergency and this outbreak has been characterized as a pandemic by the World Health Organization (WHO). Studies have suggested that investigational product favipiravir can improve the recovery of patients with mild disease and reduce the treatment duration from less than 11 days. The main purpose of this study is to obtain efficacy and safety data for favipiravir use in the Turkish patient cohort diagnosed with COVID-19 and decided to be treated with Favipiravir before enrollment to this observational study. This study is designed as an observational drug study which will evaluate the safety and efficacy of favipiravir in patients and diagnosed with COVID-19 and older than 15 years of age. This study is designed as an observational drug study to evaluate the safety and efficacy of favipiravir in patients diagnosed with COVID-19 and older than 15 years of age with a favipiravir treatment decision. Patients who have already had a routine favipiravir treatment decision or favipiravir treatment started will be included in this study. A total of 1000 female and male patients aged 15 years or older will be included in the study. The planned observation duration for each patient is 7 days. This study will be conducted in 14 sites.
Interventions
DRUGFavipiravir
Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir.
Sponsors
Hacettepe University
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Umraniye Education and Research Hospital
Istanbul Training and Research Hospital
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Tepecik Training and Research Hospital
Istanbul University - Cerrahpasa
Ankara University
Ankara City Hospital Bilkent
Ankara Training and Research Hospital
Ege University Hospital (Application and Research Center)
Derince Training and Research Hospital
Istanbul University
Kayseri City Hospital
Ministry of Health, Turkey
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients, diagnosed with Covid-19 disease who are 15 years of age or older at the time of enrollment * Patients who have understood all study procedures that will be applied under the study protocol * Patients with confirmed diagnosis of COVID-19 by PCR and/or other accepted methods and have a treatment decision with favipiravir * Patients who will accept oropharyngeal sample and venous blood sample collection periodically within the scope of the study protocol
Exclusion criteria
* Patients who are pregnant or females who are breast feeding * Patients under the age of 15
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to recovery (discharge) | 7 days | The evaluation of the recovery discharge until the 7th day of hospitalization after the initiation of treatment. |
| Decrease in viral load | 7 days | The evaluation of decrease in viral load until 7th day hospitalization after the initiation of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of occurrence of thrombocytopenia from baseline | 7 days | Clinical evaluation of occurrence of thrombocytopenia from baseline until the end of study. |
| Changes in alanine aminotransferase (ALT) levels from baseline | 7 days | Clinical evaluation of ALT levels from baseline until the end of study. |
| Changes in aspartate aminotransferase (AST) levels from baseline | 7 days | Clinical evaluation of AST levels from baseline until the end of study. |
| Changes in C-reactive protein (CRP) levels from baseline | 7 days | Clinical evaluation of CRP levels from baseline until the end of study. |
| Changes in level of D-dimer levels from baseline | 7 days | Clinical evaluation of D-dimer levels from baseline until the end of study. |
| Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment | 7 days | Number/characteristics of Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment due to study drug from baseline until the end of study. |
| Changes in partial thromboplastin time (PTT) values from baseline | 7 days | Clinical evaluation of PTT values for blood to coagulate from baseline until the end of study. |
| Changes in blood pressure from baseline | 7 days | Clinical evaluation of systolic and diastolic blood pressure levels from baseline until the end of study. |
| Changes in respiratory rate from baseline | 7 days | Clinical evaluation of respiratory rate levels from baseline until the end of study. |
| Changes in pulse oximetry from baseline | 7 days | Clinical evaluation of pulse oximetry levels from baseline until the end of study. |
| Changes in fever from baseline | 7 days | Clinical evaluation of changes in fever from baseline until the end of study. |
| Changes in prothrombin time (PT) values from baseline | 7 days | Clinical evaluation of PT values for blood to coagulate from baseline until the end of study. |
| Frequency of occurrence of lymphopenia from baseline | 7 days | Clinical evaluation of occurrence of lymphopenia from baseline until the end of study. |
Countries
Turkey (Türkiye)
Outcome results
None listed